Anavex Life Sciences Corp (AVXL)

[jimmy667]

I agree with this post. On the very first success of blarcamesine in a controlled meaningful clinical trial, Anavex, her IP, and postulated MOAs would be fundamentally re-evaluated. Possibly over correct to the upside but it would rest sustainably at a much higher valuation. The value of a Company is not calculated by daily prices but what investors are willing to pay for it on average over many months and years. For example another under the radar company Arrowhead Pharma less than 2 years ago traded for years at a market cap of where Anavex has been for years. As its novel approach was validated it was fundamentally in increments revalued from around $200 mm to $1.3 billion when I first brought it to this discussion board's attention then to $7 billion over the next 12 months and now after the market correction currently trades at $4.5 billion. Anyone with Y Charts can do a 10 market cap chart and compare with Anavex or use a 10 year price chart and extrapolate. The paths are very similar up to the point that ARWR showed it first validating clinical results. I hope some of you have followed or invested in Arrowhead. I got a message from one of you that got in at $13 when I recommended it and rode it to $70.
Anavex I believe is following and will follow the same careful under the radar path as Arrowhead and will be a winner of roughly the same magnitude.